Are you a healthcare provider?
This site is intended for U.S. healthcare providers only.
By clicking YES, you attest you are a healthcare provider licensed in the U.S.
Don’t let your patients with carcinoid syndrome symptoms rely on rescue medication alone.
*Least squares (LS) (adjusted) mean (95% confidence interval [CI]) treatment difference = -14.8% (-26.8% to -2.8%); P=0.017.
The average daily frequencies of diarrhea and flushing events in patients treated with Somatuline Depot (and rescue medication) were numerically lower relative to patients treated with placebo (and rescue medication), but were not statistically significantly different via hierarchical testing.
Please see ELECT trial study design and Patient Information below.
Patients were excluded if they had4:
— | History of carcinoid syndrome refractory to treatment with conventional doses of SSA |
— | Treatment with interferon, chemotherapy, and/or peptide receptor radionuclide therapy, and/or tumor debulking <3 months before study entry |
— | History of hepatic arterial embolization, hepatic arterial chemoembolization, and/or selective internal radiation therapy <6 months before study entry |
*ELECT=Evaluating Lanreotide Efficacy and safety as a Carcinoid-syndrome Treatment.4
†Administered every 28 days by deep subcutaneous injection, with access to short-acting octreotide as rescue medication.4
‡Analysis of variance and ANCOVA models were applied using Statistical Analysis System (SAS®) version 8 or higher.4
Hear key opinion leader Dr. Li discuss treatment options for a hypothetical patient with
carcinoid syndrome.
To report SUSPECTED ADVERSE REACTIONS, contact Ipsen Biopharmaceuticals, Inc. at 1-855-463-5127 or FDA at 1-800-FDA-1088 or www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program.
SOMATULINE® DEPOT (lanreotide) is a somatostatin analog indicated for:
Please click here for the full Prescribing Information and Patient Information.
References: